| PICP | HCM patients | Plasma | PICP ↑ | [10] |
| Hypertension patients | Serum | PICP ↑ | [11] |
| HF rats | Plasma | PICP ↓ | [12] |
| HF patients | Serum | PICP ↑ | [13] |
| PINP | HFrEF patients | Serum | PINP ↑ | [18] |
| MI rats | Plasma | PINP ↑ | [19] |
| HCM patients | Serum | Not predictive in fibrosis | [20] |
| PIIINP | DCM patients | Serum | PIIINP ↑ | [25] |
| HFrEF patients | Serum | PIIINP ↑, positively associated with diastolic function | [26] |
| CoA patients | Serum | PIIINP ↑, positively associated with LVMI and RWT | [27] |
| Hypertension patients | Serum | PIIINP ↑, inversely associated with diastolic functions | [28] |
| MI rats | Serum | PIIINP ↑ | [29] |
| CITP | HF patients | Serum | CITP ↑ | [20] |
| HF and AF patients | Serum | CITP ↑ | [32-33] |
| DCM patients | Serum | Not predictive in fibrosis | [34] |
| AMI patients | Serum | CITP ↑, predicts cardiovascular mortality | [35] |
| MMPs | HCM patients | Serum | MMP-2 ↓, MMP-9 was positively associated with fibrosis | [44] |
| systolic HF patients | Serum | MMP-1↑ | [45-46] |
| DM rats | Myocardial tissues | MMP2↓, MMP7, MMP11, MMP13, MMP16↑ | [47] |
| TIMPs | 2K1C hypertension rats | Myocardial tissues | TIMP-4↑ | [58] |
| TTC patients | Serum | TIMP-1 and MMP-2 ↑ | [59] |
| HF patients | Serum | TIMP-1↑ | [60] |
| TGF-β | MI mice | Myocardial tissues | anti-TGF-β treated: collagen production ↓, matrix-metalloproteinase ↑ | [66] |
| Pressure-overload rats | Myocardial tissues | anti-TGF-β treated: fibroblast activation ↓, collagen mRNA induction ↓ | [67] |
| TAC mice | Myocardial tissues | anti-TGF-βtreated: perivascular and interstitial fibrosis ↓ | [68] |
| Smads | TAC mice | Cardiac tissues | Smad3 or Smad2/3 deletion: cardiac fibrosis↓ | [72] |
| Smad3-deficient mice | Myocardial tissues | Collagen content and deposition ↓ | [73] |
| CTGF | DCM rats | Myocardial tissues | CTGF/CCN2 gene silencing: cardiac function ↑, myocardial fibrosis and left ventricular hypertrophy ↓ | [81] |
| MI rats | Myocardial tissues | CTGF ↑ | [83] |
| Chronic HF patients | Plasma | CTGF ↑ | [84] |
| Corin | HF patients | Plasma | Corin ↓ | [85] |
| HF canines | Myocardial tissues | Corin ↓ | [89] |
| HCM disease | Cardiomyocytes | Corin↑ | [90] |
| EndoMT | ISO-induced fibrosis | Myocardial tissues | α-SMA and vimentin: ↑ with a peak on day 3, and then gradually↓ | [92] |
| DCM rats | Myocardial tissues | a-SMA, fibronectin and vimentin↑ | [93] |
| In vitro | Mouse embryonic fibroblasts | Vimentin deletion: WF-A did not change half-lives of collagen mRNAs | [94] |
| Gal-3 | Myocardial I/R injury rats | Myocardial tissues | Gal-3 ↑ | [102] |
| AMI patients | Serum | Gal-3 ↑ after AMI and then ↓ within 5 days | [103] |
| Acute HF patients | Serum | Gal-3 ↑ | [104] |
| CAD patients | Plasma | Gal-3 is positively correlated with cardiovascular deaths | [105] |
| TNF-α and interleukin | Cardiomyocyte fibrosis | Cardiomyocytes | TNF-α, IL-6 IL-1β levels and collagen I and III mRNA expressions ↑ | [108] |
| HCM patients | Plasma | IL-4, IL-6, and IL-10 ↑ | [97] |
| IL-11 knockout mice | Myocardial tissues | Fibrosis↓ after either transverse aortic constriction or AngII infusion | [109] |
| Other Molecules | HFrEF patients | Serum | RLN1↑ | [115] |
| ISO-induced cardiac fibrosis | Myocardial tissues | GSHR deletion: myocardial fibrosis ↑ | [116] |
| VHD mice | Myocardial tissues | ADAMTS-1↑ | [117] |